Search hospitals > Ohio > Columbus
Ohio State University Comprehensive Cancer Center
Claim this profileColumbus, Ohio 43210
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
806 reported clinical trials
145 medical researchers
Summary
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 830 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Alice Mims, Uma Borate, MD, and Michael V Knopp, MD, PhD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Floor Backes, MDOhio State University Comprehensive Cancer Center2 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
22 reported clinical trials
60 drugs studied
Alice MimsOhio State University Comprehensive Cancer Center6 years of reported clinical research
Expert in Acute Myelogenous Leukemia
Expert in Acute Myeloid Leukemia
19 reported clinical trials
42 drugs studied
Uma Borate, MDOhio State University Comprehensive Cancer Center4 years of reported clinical research
Studies Acute Myeloid Leukemia
Studies Acute Myelogenous Leukemia
17 reported clinical trials
31 drugs studied
Michael V Knopp, MD, PhDThe Ohio State University Wexner Medical Center3 years of reported clinical research
Studies Anterior Cruciate Ligament Injury
Studies Digital PET/CT Imaging
15 reported clinical trials
35 drugs studied
Clinical Trials running at Ohio State University Comprehensive Cancer Center
Lung Cancer
Breast Cancer
Breast cancer
Ovarian Cancer
Prostate Cancer
Skin Cancer
Esophageal cancer
Chronic Lymphocytic Leukemia
Cancer
Fallopian Tube Cancer
PBF-1129 + Nivolumab
for Lung Cancer
This trial is testing PBF-1129 and nivolumab in patients with advanced lung cancer. The goal is to see if these drugs can work together to stop cancer growth and boost the immune system's ability to fight the cancer. Nivolumab has shown effectiveness in treating various cancers, including non-small cell lung cancer.
Recruiting3 awards Phase 122 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ohio State University Comprehensive Cancer Center?
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 830 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Alice Mims, Uma Borate, MD, and Michael V Knopp, MD, PhD.
Where is Ohio State University Comprehensive Cancer Center located?
The Ohio State University Comprehensive Cancer Center is located at 300 West 10th Avenue, Columbus, OH 43210. For access, take Medical Center Drive to Dodd Drive, turn left, and follow signs to the Wexner Medical Center Garage. Alternatively, use Kinnear Road to King Avenue, turn left onto King, and then left onto Cannon Drive to reach the hospital.
Who should I call to ask about financial aid or insurance network?
**Ohio State University Comprehensive Cancer Center - Contact Information**
- **Financial Counseling Department:** 614-293-0860
- **Financial Assistance:** 614-293-0860
- **Medication Assistance Program:** 614-293-3868
- **Patient Billing Customer Service:** 614-293-2100
- **Medicaid Assistance:** 614-293-0860, option 2
For more details or to apply for financial assistance, please visit the Financial Assistance page on our website.
What insurance does Ohio State University Comprehensive Cancer Center accept?
The Ohio State University Comprehensive Cancer Center (OSUCCC) accepts a wide range of insurance plans, including Medicaid, Medicare, and various exchange health plans. For Medicaid, accepted plans include AmeriHealth Caritas, Buckeye Community Health Plan, CareSource, Humana Healthy Horizons, and Medicaid Ohio Traditional. Medicare recipients are covered under all traditional plans and Medigap coverage, while exchange health plans accepted include CareSource Marketplace, Molina Healthcare of Ohio, and Buckeye AmBetter.
What awards or recognition has Ohio State University Comprehensive Cancer Center received?
The Ohio State University Comprehensive Cancer Center (OSUCCC) in Columbus, Ohio, has been a National Cancer Institute (NCI)-designated comprehensive cancer center since 1976, showcasing its commitment to excellence in research, patient care, education, and community outreach. It has garnered significant funding for research and care, including NCI grants for phase 1, 2, and 3 clinical trials of novel cancer drugs. Additionally, the OSUCCC supports initiatives such as the Pelotonia Institute for Immuno-Oncology and the Center for Cancer Engineering.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.